Xcopri Approval History

FDA Approved: Yes (First approved November 21, 2019)
Brand name: Xcopri
Generic name: cenobamate
Dosage form: Tablets
Company: SK Life Science, Inc.
Treatment for: Seizures

Xcopri (cenobamate) is an antiepileptic drug for the treatment of partial-onset seizures in adult patients.

Development History and FDA Approval Process for Xcopri

Date	Article
Nov 21, 2019	FDA Approves Xcopri (cenobamate) for the Treatment of Partial-Onset Seizures in Adults
Nov 13, 2019	Results of a Randomized Study of the Safety and Efficacy of Cenobamate in Adults with Uncontrolled Focal Seizures Published in The Lancet Neurology
Feb  4, 2019	SK Life Science Announces FDA Acceptance of NDA Submission for Cenobamate, an Investigational Antiepileptic Drug

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer